United Therapeutics to highlight innovative pulmonary research at ATS 2025 conference in San Francisco

United Therapeutics Corporation  announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Francisco on May 16-21, 2025.

At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the ATS Research Program Benefit Networking Event, and the company is hosting the Jenesis Innovative Research Awards Ceremony. “Our series of posters and presentations at ATS will showcase the most recent findings on several products across our core portfolio and ongoing development pipeline,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics. “We are pleased to present additional interim efficacy data from the ADVANCE EXTENSION open-label study evaluating ralinepag for pulmonary arterial hypertension, which has the potential, through once-daily dosing, to fundamentally change the positioning of prostacyclins in the treatment paradigm.”

Thematic Poster Session
Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT
A48/P1624 – TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data.
Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital

Thematic Poster Session
Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT
A48/P1623 – TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis: Preliminary Baseline Demographics.
Presented by Steven D. Nathan, M.D., Inova Fairfax Hospital

Poster Discussion Session
Sunday, May 18, 2:15 p.m. to 4:15 p.m. PT
A104/908 – Expert Nurse Insights on the Future of Parenteral Prostacyclin Pumps for Pulmonary Arterial Hypertension.
Presented by Lori Reed, N.P., Piedmont Healthcare

Rapid Abstract Poster Discussion Session
Monday, May 19, 9:15 a.m. to 11:15 a.m. PT
B26/410 – The Minimal Important Difference in NT-proBNP in Various Forms of Pulmonary Hypertension.
Presented by Stephen Mathai, M.D., MHS, Johns Hopkins School of Medicine

Mini Symposium
Monday, May 19, 3:15 p.m. to 3:27 p.m. PT
B96 – Ralinepag Treatment to Achieve and Maintain REVEAL Lite 2 Low Risk Status: Interim Results of ADVANCE EXTENSION.
Presented by Ray Benza, M.D., Icahn School of Medicine at Mount Sinai Center

Thematic Poster Session
Tuesday, May 20, 11:30 a.m. to 1:15 p.m. PT
C58/P1412 – Hemodynamic Phenotypes of Interstitial Lung Disease Patients Enrolled in the PHINDER Study.
Presented by Debabrata Bandyopadhyay, MBBS, M.D., FCCP, FRCP, FACP, University of South Florida

Thematic Poster Session
Tuesday, May 20, 11:30 a.m. to 1:15 p.m. PT
C58/P1403 – Screening of Pulmonary Hypertension in Interstitial Lung Disease in the PHINDER Study: A Comparison of Physician Gestalt with Hemodynamics.
Presented by Sandeep Sahay, M.D., Houston Methodist Hospital

Thematic Poster Session
Tuesday, May 20, 11:30 a.m. to 1:15 p.m. PT
C57/P1390 – Efficacy and Safety of Oral Treprostinil in Intermediate-High Risk Pulmonary Arterial Hypertension: A FREEDOM-EV Subgroup Analysis.
Presented by Jim White, M.D., Ph.D., University of Rochester

Thematic Poster Session
Tuesday, May 20, 11:30 a.m. to 1:15 p.m. PT
C57/P1393 – Thrombocytopenia Associated with Epoprostenol and Treprostinil Alone and in Combination with Sotatercept.
Presented by Mardi Gomberg-Maitland, M.D., M.Sc., George Washington University